# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Baird analyst Joel Beatty maintains Calidi Biotherapeutics (AMEX:CLDI) with a Outperform and lowers the price target from $4...
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of ...
U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling around 0.3% on Tuesday. The Dow traded up 0.0...
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter...